3.21
price up icon5.25%   0.16
 
loading
Precedente Chiudi:
$3.05
Aprire:
$3.09
Volume 24 ore:
632.08K
Relative Volume:
1.50
Capitalizzazione di mercato:
$45.79M
Reddito:
-
Utile/perdita netta:
$-40.94M
Rapporto P/E:
-0.8359
EPS:
-3.84
Flusso di cassa netto:
$-22.97M
1 W Prestazione:
+36.60%
1M Prestazione:
+122.92%
6M Prestazione:
-46.50%
1 anno Prestazione:
-51.87%
Intervallo 1D:
Value
$3.0311
$3.40
Intervallo di 1 settimana:
Value
$2.2908
$3.48
Portata 52W:
Value
$1.11
$17.88

Annovis Bio Inc Stock (ANVS) Company Profile

Name
Nome
Annovis Bio Inc
Name
Telefono
484-875-3192
Name
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
Dipendente
6
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-11
Name
Ultimi documenti SEC
Name
ANVS's Discussions on Twitter

Confronta ANVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ANVS
Annovis Bio Inc
3.21 45.79M 0 -40.94M -22.97M -3.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-10 Downgrade D. Boral Capital Buy → Hold
2024-10-25 Aggiornamento Maxim Group Hold → Buy
2023-12-29 Iniziato Canaccord Genuity Buy
2021-07-07 Reiterato Maxim Group Buy

Annovis Bio Inc Borsa (ANVS) Ultime notizie

pulisher
Jun 06, 2025

Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MyChesCo

Jun 06, 2025
pulisher
Jun 06, 2025

Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -

Jun 06, 2025
pulisher
Jun 05, 2025

Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World

Jun 02, 2025
pulisher
May 28, 2025

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 26, 2025
pulisher
May 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

May 20, 2025
pulisher
May 20, 2025

Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN

May 20, 2025
pulisher
May 17, 2025

Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

May 15, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -

May 15, 2025
pulisher
May 13, 2025

Annovis Bio Appoints New Principal Financial Officer - TipRanks

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 06, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN

May 06, 2025
pulisher
Apr 30, 2025

Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -

Apr 30, 2025
pulisher
Apr 29, 2025

Annovis Bio hires new director of biostatistics amid AD trial - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Apr 29, 2025
pulisher
Apr 26, 2025

LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025
pulisher
Apr 15, 2025

Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025
pulisher
Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Annovis Bio Inc Azioni (ANVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):